Ian T. Clark, a director at Guardant Health, Inc. (NASDAQ:GH), disposed of common stock valued at approximately $735,048, according to a recent SEC filing. The transaction occurred on May 20, 2026.
Mr. Clark sold 6,876 shares at prices ranging from $106.85 to $106.99 per share, with a weighted average sale price of $106.9006. These shares were held indirectly through The Thornton-Clark Family Trust.
Following this transaction, Mr. Clark's indirect holdings amount to 2,975 shares.
In other recent news, Guardant Health received early FDA approval for its G360 Liquid CDx test, expanding its blood-based cancer testing product with genomic and epigenomic analysis. The new test offers a genomic footprint 100 times wider than the previous version.
For Q1 2026, Guardant Health reported revenue of $302 million, beating estimates by 8.04%. However, EPS of -$0.85 missed the forecast of -$0.81. TD Cowen reiterated a Buy rating with a $127 price target.
